Physician
Arthritis and Osteoporosis Medical Center, INC
Arthritis and Osteoporosis Medical Center, INC was paid $10.88M by Medicaid between Jan 2018 and Dec 2024, across 49 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 40% of everything it billed.
33Billing provider infoARTHRITIS AND OSTEOPOROSIS MEDICAL CENTER, INC
MONTEREY PARK, CA 91754
MONTEREY PARK, CA 91754
33aNPI1245340231assigned 08/30/2006
33bProvider typeRheumatology Physician
28Total paid$10.88M
24GClaims204,642
24DCodes billed49
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rheumatology Physician providers in California
Rank by total paid#6 of 147
Median peer was paid$43K
This provider vs. median251×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,198 | $1.27M | |
| 2019 | 28,588 | $1.49M | |
| 2020 | 24,816 | $1.33M | |
| 2021 | 23,897 | $1.42M | |
| 2022 | 28,581 | $1.62M | |
| 2023 | 35,640 | $1.97M | |
| 2024incomplete | 33,922 | $1.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 40% | 57,268 | 55,280 | $4.37M |
| 20611 | 7.1% | 20,697 | 8,665 | $774K | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 6.6% | 1,375 | 1,305 | $722K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.6% | 6,458 | 6,444 | $721K |
| G9006 | Coordinated care fee, home monitoring | 6.4% | 2,706 | 2,446 | $692K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 5.9% | 7,097 | 6,657 | $637K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.9% | 11,267 | 10,953 | $528K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 4.2% | 820 | 799 | $456K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.0% | 2,702 | 2,700 | $215K |
| 96415 | 1.9% | 6,461 | 6,065 | $204K | |
| 73120 | 1.5% | 14,035 | 7,061 | $168K | |
| J0897 | Injection, denosumab, 1 mg | 1.4% | 737 | 734 | $157K |
37 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 7,117 | $126K |
| 73620 | 1.2% | 12,941 | $125K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 9,825 | $121K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 4,999 | $112K |
| J7332 | Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg | <1% | 1,827 | $94K |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 3,267 | $88K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 56 | $82K |
| 73560 | <1% | 6,055 | $70K | |
| 20610 | <1% | 1,572 | $50K | |
| 20552 | <1% | 1,442 | $39K | |
| 20553 | <1% | 993 | $37K | |
| J3262 | Injection, tocilizumab, 1 mg | <1% | 27 | $36K |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | <1% | 1,499 | $34K |
| 72100 | <1% | 2,034 | $33K | |
| 77080 | <1% | 1,545 | $28K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,388 | $28K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 235 | $23K |
| 73030 | <1% | 1,403 | $22K | |
| 72040 | <1% | 968 | $19K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,940 | $14K |
| J0490 | Injection, belimumab, 10 mg | <1% | 29 | $11K |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 1,013 | $10K |
| 72200 | <1% | 635 | $8K | |
| 73502 | <1% | 288 | $6K | |
| 99205 | Prolong outpt/office vis | <1% | 28 | $5K |
| 72070 | <1% | 193 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,940 | $2K |
| 96401 | <1% | 93 | $2K | |
| 73600 | <1% | 52 | $478.32 | |
| 20606 | <1% | 15 | $456.05 | |
| 99442 | <1% | 14 | $395.04 | |
| J9250 | Methotrexate sodium, 5 mg | <1% | 1,264 | $373.63 |
| 73100 | <1% | 28 | $288.90 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12 | $259.40 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 127 | $162.76 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 128 | $64.70 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 27 | $41.77 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHO, GERALD (MEDICAL DIRECTOR)
Parent organizationARTHRITIS AND OSTEOPOROSIS MEDICAL CENTERS, INC
| Provider | Location | Paid |
|---|---|---|
| Arthritis and Osteoporosis Medical Center, INC | La Palma, CA | $148K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.